# US 2026/0083678 A1 · Oral Dosing of GLP-1 Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083678 A1
- Document ID: US20260083678A1
- Status: Published application
- Kind: A1
- Application number: 19/407,705
- Filed: 2025-12-03
- Published: 2026-03-26
- Earliest claimed: 2013-05-02
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Flemming S. Nielsen; Per Sauerberg
- Web page: https://patentgrep.com/patent/US20260083678A1

## CPC

- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/26: Glucagons
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to improved uses of GLP-1 peptides in oral therapy.

## Claims

### Claim 1

A solid composition comprising a GLP-1 peptide and an enhancer for use as a medicament by oral administration,
wherein said peptide has plasma half-life in humans of at least 60 hours,
wherein said composition is administered at least 3 times, and
wherein a) said composition is administered every second day or more often; or b) said composition is administered such that the ratio between the plasma half-life in days in humans of said peptide and the dosing interval in days of said composition is more than 2:1.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein said composition is in the form of a tablet.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein said composition is administered at least 5 times, such as at least 7 times or at least 10 times.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein said composition is administered twice daily, once daily, or every second day.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein said enhancer is a salt of N-(8-(2-hydroxybenzoyl)amino) caprylic acid, such as SNAC.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the amount of SNAC is 100-500 mg SNAC, or wherein the amount of SNAC is 50-90% (w/w) of said composition.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein said enhancer is a salt of capric acid, such as sodium caprate.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein said peptide has plasma half-life in humans of at least 72 hours.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein said peptide is administered in an amount of 0.01-100 mg, such as 2-60 mg, or such as such as at least 5 mg or at least 10 mg.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein said composition comprises 1-100 mg GLP-1 peptide and 100-500 mg or 50-90% (w/w) SNAC.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein said peptide is semaglutide.

### Claim 12 (depends on 1)

The composition according to claim 1, wherein said composition comprises 1-100 mg semaglutide and 100-500 mg or 50-90% (w/w) SNAC, or wherein said composition comprises 2-60 mg semaglutide and 200-400 mg SNAC.

### Claim 13 (depends on 1)

The composition according to any claim 1, wherein said composition further comprises one or more pharmaceutically acceptable excipients.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein said composition is for use in the treatment or prevention of diabetes and/or obesity.

### Claim 15

A method of oral administration of a solid composition comprising a GLP-1 peptide and an enhancer to a subject in need thereof, wherein said peptide has plasma half-life in humans of at least 60 hours, wherein said composition is administered at least 3 times, and wherein a) said composition is administered every second day or more often; or b) said composition is administered such that the ratio between the plasma half-life in days in humans of said peptide and the dosing interval in days of said composition is more than 2:1.
